Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma, H-share: 01276; A-share: 600276) disclosed a Next Day Disclosure Return on 11 June 2026, detailing an on-market share repurchase carried out the same day on the Shanghai Stock Exchange.

The company bought back 150,000 A-shares earmarked for its Employee Stock Ownership Schemes. Transaction prices ranged from RMB 46.85 to RMB 46.91 per share, with a volume-weighted average price of RMB 46.89. Total consideration amounted to RMB 7.03 million.

Following the repurchase, the number of issued shares (excluding treasury shares) fell from 6.37 billion to 6.37 billion, representing a 0.0024% reduction. Treasury shares increased to 8.19 million, while the total issued share count, including treasury shares, remained unchanged at 6.38 billion. No shares were repurchased for cancellation.

The board confirmed that the transaction was duly authorised and executed in compliance with all applicable listing rules and domestic regulations.